Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
53
ASBP Quote, Financials, Valuation and Earnings
Last price:
$0.11
Seasonality move
:
-30.52%
Day range:
$0.10 - $0.12
52-week range:
$0.07 - $15.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2,053.63x
P/B ratio:
--
Volume:
19.5M
Avg. volume:
44.5M
1-year change:
-99.06%
Market cap:
$11.6M
Revenue:
--
EPS (TTM):
-$1.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
IVVD
Invivyd, Inc.
|
$13.1M | -$0.10 | 2.86% | -28.53% | $10.00 |
|
MSPR
MSP Recovery
|
-- | -- | -- | -- | -- |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-- | -$0.45 | -- | -17.14% | $46.00 |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
-- | -$53.60 | -- | -928.79% | -- |
|
TSHA
Taysha Gene Therapies, Inc.
|
$1.4M | -$0.09 | -6.58% | -6.87% | $10.79 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
$0.11 | -- | $11.6M | -- | $0.00 | 0% | 2,053.63x |
|
IVVD
Invivyd, Inc.
|
$2.69 | $10.00 | $627.1M | -- | $0.00 | 0% | 7.12x |
|
MSPR
MSP Recovery
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
OLMA
Olema Pharmaceuticals, Inc.
|
$26.23 | $46.00 | $1.8B | -- | $0.00 | 0% | -- |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
$0.66 | -- | $335K | -- | $0.00 | 0% | -- |
|
TSHA
Taysha Gene Therapies, Inc.
|
$5.83 | $10.79 | $1.6B | -- | $0.00 | 0% | 259.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
-303.41% | 5.459 | 84.54% | 0.14x |
|
IVVD
Invivyd, Inc.
|
2.8% | 0.816 | 1.14% | 2.13x |
|
MSPR
MSP Recovery
|
-- | 0.000 | -- | -- |
|
OLMA
Olema Pharmaceuticals, Inc.
|
1.44% | 1.569 | 0.67% | 7.90x |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
-- | 2.560 | -- | 2.60x |
|
TSHA
Taysha Gene Therapies, Inc.
|
24.09% | 3.295 | 7.76% | 10.40x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
$900 | -$1.1M | -2180.87% | -- | -60289.47% | -$1.1M |
|
IVVD
Invivyd, Inc.
|
$11.6M | -$11M | -85.47% | -87.85% | -83.96% | -$8.3M |
|
MSPR
MSP Recovery
|
-- | -- | -- | -- | -- | -- |
|
OLMA
Olema Pharmaceuticals, Inc.
|
-$43K | -$45.9M | -45.23% | -45.61% | -- | -$34.5M |
|
SLRX
Salarius Pharmaceuticals, Inc.
|
-$1.1K | -$895.1K | -291.67% | -316.09% | -- | -$1.6M |
|
TSHA
Taysha Gene Therapies, Inc.
|
-$286K | -$34M | -49.9% | -73.14% | -1347.08% | -$24.3M |
Aspire Biopharma Holdings, Inc. vs. Competitors
-
Which has Higher Returns ASBP or IVVD?
Invivyd, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of -79.75%. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Invivyd, Inc.'s return on equity of -87.85%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M IVVDInvivyd, Inc.88.43% -$0.06 $95.7M -
What do Analysts Say About ASBP or IVVD?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Invivyd, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 271.75%. Given that Invivyd, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Invivyd, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 IVVDInvivyd, Inc.3 1 0 -
Is ASBP or IVVD More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Invivyd, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ASBP or IVVD?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Invivyd, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Invivyd, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or IVVD?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are smaller than Invivyd, Inc. quarterly revenues of $13.1M. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Invivyd, Inc.'s net income of -$10.5M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Invivyd, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 2,053.63x versus 7.12x for Invivyd, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.2,053.63x -- $1.9K -$1.9M IVVDInvivyd, Inc.7.12x -- $13.1M -$10.5M
-
Which has Higher Returns ASBP or MSPR?
MSP Recovery has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of --. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat MSP Recovery's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M MSPRMSP Recovery-- -- -- -
What do Analysts Say About ASBP or MSPR?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand MSP Recovery has an analysts' consensus of -- which suggests that it could fall by --. Given that Aspire Biopharma Holdings, Inc. has higher upside potential than MSP Recovery, analysts believe Aspire Biopharma Holdings, Inc. is more attractive than MSP Recovery.
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 MSPRMSP Recovery0 0 0 -
Is ASBP or MSPR More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison MSP Recovery has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock ASBP or MSPR?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MSP Recovery offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. MSP Recovery pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or MSPR?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are larger than MSP Recovery quarterly revenues of --. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than MSP Recovery's net income of --. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while MSP Recovery's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 2,053.63x versus -- for MSP Recovery. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.2,053.63x -- $1.9K -$1.9M MSPRMSP Recovery-- -- -- --
-
Which has Higher Returns ASBP or OLMA?
Olema Pharmaceuticals, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of --. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Olema Pharmaceuticals, Inc.'s return on equity of -45.61%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M OLMAOlema Pharmaceuticals, Inc.-- -$0.49 $312M -
What do Analysts Say About ASBP or OLMA?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Olema Pharmaceuticals, Inc. has an analysts' consensus of $46.00 which suggests that it could grow by 75.37%. Given that Olema Pharmaceuticals, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Olema Pharmaceuticals, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 OLMAOlema Pharmaceuticals, Inc.8 0 0 -
Is ASBP or OLMA More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Olema Pharmaceuticals, Inc. has a beta of 1.870, suggesting its more volatile than the S&P 500 by 86.967%.
-
Which is a Better Dividend Stock ASBP or OLMA?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Olema Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Olema Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or OLMA?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are larger than Olema Pharmaceuticals, Inc. quarterly revenues of --. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Olema Pharmaceuticals, Inc.'s net income of -$42.2M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Olema Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 2,053.63x versus -- for Olema Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.2,053.63x -- $1.9K -$1.9M OLMAOlema Pharmaceuticals, Inc.-- -- -- -$42.2M
-
Which has Higher Returns ASBP or SLRX?
Salarius Pharmaceuticals, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of --. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Salarius Pharmaceuticals, Inc.'s return on equity of -316.09%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M SLRXSalarius Pharmaceuticals, Inc.-- -$1.81 $4.2M -
What do Analysts Say About ASBP or SLRX?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Salarius Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could grow by 59233.61%. Given that Salarius Pharmaceuticals, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Salarius Pharmaceuticals, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 SLRXSalarius Pharmaceuticals, Inc.0 0 0 -
Is ASBP or SLRX More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Salarius Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.225%.
-
Which is a Better Dividend Stock ASBP or SLRX?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Salarius Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Salarius Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or SLRX?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are larger than Salarius Pharmaceuticals, Inc. quarterly revenues of --. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is lower than Salarius Pharmaceuticals, Inc.'s net income of -$873.5K. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Salarius Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 2,053.63x versus -- for Salarius Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.2,053.63x -- $1.9K -$1.9M SLRXSalarius Pharmaceuticals, Inc.-- -- -- -$873.5K
-
Which has Higher Returns ASBP or TSHA?
Taysha Gene Therapies, Inc. has a net margin of -97394.74% compared to Aspire Biopharma Holdings, Inc.'s net margin of -1353.58%. Aspire Biopharma Holdings, Inc.'s return on equity of -- beat Taysha Gene Therapies, Inc.'s return on equity of -73.14%.
Company Gross Margin Earnings Per Share Invested Capital ASBPAspire Biopharma Holdings, Inc.47.37% -$0.04 -$2.8M TSHATaysha Gene Therapies, Inc.86.05% -$0.09 $288.5M -
What do Analysts Say About ASBP or TSHA?
Aspire Biopharma Holdings, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Taysha Gene Therapies, Inc. has an analysts' consensus of $10.79 which suggests that it could grow by 85%. Given that Taysha Gene Therapies, Inc. has higher upside potential than Aspire Biopharma Holdings, Inc., analysts believe Taysha Gene Therapies, Inc. is more attractive than Aspire Biopharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ASBPAspire Biopharma Holdings, Inc.0 0 0 TSHATaysha Gene Therapies, Inc.11 0 0 -
Is ASBP or TSHA More Risky?
Aspire Biopharma Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Taysha Gene Therapies, Inc. has a beta of 1.056, suggesting its more volatile than the S&P 500 by 5.563%.
-
Which is a Better Dividend Stock ASBP or TSHA?
Aspire Biopharma Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Taysha Gene Therapies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aspire Biopharma Holdings, Inc. pays -- of its earnings as a dividend. Taysha Gene Therapies, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ASBP or TSHA?
Aspire Biopharma Holdings, Inc. quarterly revenues are $1.9K, which are larger than Taysha Gene Therapies, Inc. quarterly revenues of --. Aspire Biopharma Holdings, Inc.'s net income of -$1.9M is higher than Taysha Gene Therapies, Inc.'s net income of -$32.7M. Notably, Aspire Biopharma Holdings, Inc.'s price-to-earnings ratio is -- while Taysha Gene Therapies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aspire Biopharma Holdings, Inc. is 2,053.63x versus 259.98x for Taysha Gene Therapies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ASBPAspire Biopharma Holdings, Inc.2,053.63x -- $1.9K -$1.9M TSHATaysha Gene Therapies, Inc.259.98x -- -- -$32.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
